What are the differential diagnoses for bullous pemphigoid?

Differential Diagnosis of Bullous Pemphigoid

The key differential diagnoses for bullous pemphigoid include other autoimmune subepidermal blistering diseases (epidermolysis bullosa acquisita, mucous membrane pemphigoid, linear IgA disease, anti-p200 pemphigoid), as well as non-autoimmune blistering conditions that must be systematically excluded using clinical features and immunopathological testing. 1, 2

Autoimmune Subepidermal Blistering Diseases

These conditions overlap significantly with BP in morphology and immunopathology, making differentiation critical:

Epidermolysis Bullosa Acquisita (EBA)

• Key distinguishing features: Trauma-induced blisters on extensor surfaces, atrophic scarring (absent in BP), nail dystrophy, and milia formation 2
• Immunopathology: Linear IgG at basement membrane zone on DIF (similar to BP), BUT on salt-split skin IIF, antibodies bind to the dermal/floor side of the split (versus epidermal/roof side in BP) 1, 3
• Advanced testing: N-serration pattern analysis and fluorescence overlay antigen mapping can differentiate by showing IgG deposits below the lamina densa in EBA versus above in BP 1, 4

Mucous Membrane Pemphigoid (MMP)

• Clinical distinction: Predominant mucosal involvement with scarring (ocular, oral, genital), whereas BP has rare and non-scarring mucosal lesions 1, 2
• Immunopathology: Antilaminin-332 MMP shows dermal-side binding on salt-split skin, distinguishing it from BP 1

Linear IgA Disease (LAD)

• Immunopathology: The definitive differentiator is DIF showing only IgA deposits at the basement membrane zone (no IgG or C3 alone), whereas BP shows linear IgG and/or C3 2, 5
• Clinical overlap: Can present similarly with tense bullae and urticarial lesions

Anti-p200 Pemphigoid

• Differentiation: Salt-split skin shows dermal-side IgG binding, distinguishing it from BP's epidermal-side pattern 1

Non-Bullous Variants and Clinical Mimics

Atypical BP Presentations

BP itself has multiple clinical variants that can mimic other conditions 1:

• Nonbullous BP: Excoriations, prurigo nodularis-like lesions, eczematous or urticarial lesions without blisters (affects 21.6% or 1 in 5 patients) 6
• Dyshidrosiform BP: Vesicles primarily on palms and soles, mimicking pompholyx 7
• Localized BP: Confined to specific body areas

Non-Autoimmune Blistering Conditions

These must be recognized and excluded before initiating immunosuppression 2:

• Infectious causes: Viral (herpes simplex, varicella-zoster) and bacterial skin infections (bullous impetigo, cellulitis with bullae)
• Inflammatory dermatoses: Erythema multiforme, contact dermatitis, severe drug eruptions
• Physical causes: Burns, insect bites, friction blisters, edema-related bullae
• Genetic disorders: Epidermolysis bullosa group (typically presents earlier in life)

Diagnostic Algorithm for Differentiation

Step 1: Clinical Assessment 1

• Age >70 years, absence of atrophic scars, absence of significant mucosal involvement, absence of predominant neck/head lesions → favors BP
• Presence of scarring, trauma-induced blisters, or extensive mucosal disease → consider EBA or MMP

Step 2: Essential Immunopathology 1, 6

• DIF on perilesional skin (most critical test): Linear IgG and/or C3 at dermoepidermal junction confirms autoimmune subepidermal disease
  • Only IgA → Linear IgA disease
  • Linear IgG/C3 → proceed to Step 3
• Histopathology: Subepidermal bullae with eosinophils/neutrophils supports BP but is not specific

Step 3: Antibody Localization 1, 6

• Salt-split skin IIF (or suction-split): IgG binding to epidermal/roof side confirms BP (77% sensitivity, 99.9% specificity)
  • Dermal/floor side binding → EBA or antilaminin-332 MMP or anti-p200 pemphigoid
• BP180 ELISA: Positive in ~80% of BP cases; useful for confirmation and monitoring but not essential for initial diagnosis 6

Step 4: Exclude Infectious/Non-Autoimmune Causes 2

• Bacterial/viral cultures if infection suspected
• Patch testing if contact dermatitis considered
• Drug history review (diuretics, psycholeptics can trigger BP) 1

Critical Pitfalls to Avoid

• Don't rely on histopathology alone: Subepidermal blistering with eosinophils is suggestive but not diagnostic—DIF is essential 1
• Don't skip salt-split skin testing: Standard IIF on intact skin has lower sensitivity; salt-split methodology is crucial for differentiating BP from EBA and other conditions 1, 3
• Don't dismiss nonbullous presentations: One in five BP patients never develops frank bullae, presenting only with pruritus, urticaria, or eczematous lesions 6
• Don't assume negative serology excludes BP: DIF remains positive in ~88% of cases even when serology is negative 6
• Don't forget drug-induced BP: Recent exposure (1-6 months) to diuretics or phenothiazines should raise suspicion 1